Skip to main content
SpringerLink
Log in

Hepatotoxizität selektiver Progesteronrezeptormodulatoren

Hepatotoxicity of selective progesterone receptor modulators

  • Arzneimitteltherapie
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Donnez J, Tatarchuk TF, Bouchard P et al (2012) PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 366:409–420

    Article  CAS  Google Scholar 

  2. Islam MS, Afrin S, Jones SI, Segars J (2020) Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev 41(5):bnaa12

    Article  Google Scholar 

  3. Kawaguchi K, Fujii S, Konishi I et al (1991) Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 419:309–315

    Article  CAS  Google Scholar 

  4. Bouchard P, Chabbert-Buffet N, Fauser BC (2011) Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 96:1175–1189

    Article  CAS  Google Scholar 

  5. Tristan M, Orozco LJ, Steed A, Ramirez-Morera A, Stone P (2012) Mifepristone for uterine fibroids. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007687.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X (2013) Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 100:1722–1726.e1-10

    Article  CAS  Google Scholar 

  7. Williams AR, Critchley HO, Osei J et al (2007) The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 22:1696–1704

    Article  CAS  Google Scholar 

  8. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC, Lumsden MA, Hapangama D, Williams AR, Critchley HO (2008) Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 93:4664–4671

    Article  CAS  Google Scholar 

  9. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA (2007) A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87:1399–1412

    Article  CAS  Google Scholar 

  10. ClinicalTrials.gov (2008) Safety of treatment of uterine fibroids with Asoprisnil. https://clinicaltrials.gov/ct2/show/NCT00156208. Zugegriffen: 15. Febr. 2021

  11. Luo X, Yin P, Coon VJ, Cheng YH, Wiehle RD, Bulun SE (2010) The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 93:2668–2673

    Article  CAS  Google Scholar 

  12. Ioffe OB, Zaino RJ, Mutter GL (2009) Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 22:450–459

    Article  CAS  Google Scholar 

  13. ClinicalTrials.gov. (2016) A phase 2, study to evaluate the safety and efficacy ProellexR(Telapristone acetate) administered vaginally in the treatment of uterine fibroids. https://clinicaltrials.gov/ct2/show/NCT02323646. Zugegriffen: 15. Febr. 2021

  14. Schutt B, Kaiser A, Schultze-Mosgau MH, Seitz C, Bell D, Koch M, Rohde B (2016) Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod 31:1703–1712

    Article  Google Scholar 

  15. Gemzell-Danielsson K, Heikinheimo O, Zatik J, Poka R, Rechberger T, Hudecek R, Petersdorf K, Ramirez F, Faustmann T, Groettrup-Wolfers E, Seitz C (2020) Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol 252:7–14

    Article  CAS  Google Scholar 

  16. Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M (2003) Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 68:1013–1017

    Article  CAS  Google Scholar 

  17. Levens ED, Potlog-Nahari C, Armstrong AY et al (2008) CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 111:1129–1136

    Article  CAS  Google Scholar 

  18. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P, VA2914 Study Group (2007) Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92:3582–3589

    Article  CAS  Google Scholar 

  19. Ekanem E, Talaulikar V (2021) Medical therapy for fibroids: what next for ulipristal acetate? Adv Ther 38:137–148

    Article  CAS  Google Scholar 

  20. Fernandez H, Schmidt T, Powell M, Costa AP, Arriagada P, Thaler C (2017) Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol 208:91–96

    Article  CAS  Google Scholar 

  21. Liu JH, Soper D, Lukes A et al (2018) Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 132:1241–1251

    Article  CAS  Google Scholar 

  22. Simon JA, Catherino W, Segars JH et al (2018) Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 131:431–439

    Article  CAS  Google Scholar 

  23. Kang S, Brinker A, Jones SC, Dimick-Santos L, Avigan MI (2020) An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with Ulipristal acetate for the treatment of uterine fibroids. Drug Saf 43:1267–1276

    Article  Google Scholar 

  24. Ali M, Al-Hendy A (2017) Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod 97:337–352

    Article  Google Scholar 

  25. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K (2009) Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 24:1870–1879

    Article  CAS  Google Scholar 

  26. Carbonell JL, Acosta R, Pérez Y, Garcés R, Sánchez C, Tomasi G (2013) Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial. ISRN Obstet Gynecol 2013:649030

    PubMed  PubMed Central  Google Scholar 

  27. Yerushalmi GM, Gilboa Y, Jakobson-Setton A et al (2014) Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril 101:496–500

    Article  CAS  Google Scholar 

  28. Stewart EA, Diamond MP, Williams ARW et al (2019) Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Hum Reprod 34:623–634

    Article  CAS  Google Scholar 

  29. Donnez J, Arriagada P, Marciniak M, Larrey D (2018) Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. https://doi.org/10.1080/14740338.2018.1550070

    Book  Google Scholar 

  30. Donnez J, Vázquez F, Tomaszewski J et al (2014) Longterm treatment of uterine fibroids with ulipristal acetate. Fertil Steril 101:1565–1573

    Article  CAS  Google Scholar 

  31. Donnez J (2018) Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril 110:593–595

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Deutschland

    Thomas Strowitzki

Authors
  1. Thomas Strowitzki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Strowitzki.

Ethics declarations

Interessenkonflikt

T. Strowitzki gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

B. Leeners, Zürich

O. Ortmann, Regensburg

C. Tempfer, Herne

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strowitzki, T. Hepatotoxizität selektiver Progesteronrezeptormodulatoren. Gynäkologische Endokrinologie 19, 228–231 (2021). https://doi.org/10.1007/s10304-021-00385-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-021-00385-8

Search

Navigation